Tigermed Completes Acquisition of Japanese CRO Micron
Deal News | Jul 29, 2025 | PR Newswire Cision Tigermed
Tigermed, a leading global provider of clinical research solutions, has successfully completed the acquisition of Micron, a Japanese Contract Research Organization specializing in medical imaging and clinical trial services. Established in 2005 and based in Tokyo, Micron is renowned for its advanced imaging expertise and pioneering practices in the fields of imaging biomarkers and AI-powered imaging support. With a workforce of over 160 employees, Micron has facilitated the successful approval of over 40 drugs and built a client base exceeding 250. This acquisition will integrate Micron into Tigermed's extensive global network, bolstering Tigermed's capabilities in the Asia-Pacific region. Key figures in the acquisition expressed optimism about the benefits of combining their strengths. Hiroaki Suzuki, President and Co-founder of Micron, emphasized the potential for growth and expansion. Michael Wen, Co-President of Tigermed, highlighted the strategic advantage of augmenting Tigermed's competitiveness through Micron's technological prowess and track record. The transaction signifies a significant step forward in Tigermed's global expansion strategy, enhancing its offerings in medical imaging and clinical services.
Sectors
- Clinical Research
- Biopharmaceuticals
- Medical Devices
Geography
- China – Tigermed is headquartered in Hangzhou, China, and plays a central role in the transaction.
- Japan – Micron is a Japanese company with headquarters in Tokyo, making Japan a critical geography for this acquisition.
- Asia-Pacific – The combined leverage and expansion across the Asia-Pacific region is a significant aspect of the acquisition's strategic intent.
Industry
- Clinical Research – This industry classification is relevant as both Tigermed and Micron operate in the field of clinical research solutions, facilitating global biopharmaceutical and medical device product development.
- Biopharmaceuticals – Micron's expertise in imaging and clinical trials significantly contributes to the development and approval of drugs within the biopharmaceutical sector.
- Medical Devices – Both companies operate within the medical devices industry, providing research and development services that support the creation and commercialization of medical device products.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Tigermed | Acquiring Company | Company | A leading global provider of clinical research solutions, aiming to enhance its medical imaging capabilities and presence in Asia-Pacific. |
| Micron | Target Company | Company | A Tokyo-based Contract Research Organization specializing in medical imaging and clinical trial services with notable expertise and a robust client base. |
| Hiroaki Suzuki | President and Co-founder of Micron | Person | Expressed optimism about the acquisition's potential for growth and expansion in collaboration with Tigermed. |
| Michael Wen | Co-President of Tigermed | Person | Highlighted Micron's strengths and the strategic fit within Tigermed’s global expansion plans. |